Claims for Patent: 7,943,341

Summary for Patent: 7,943,341

Title:	DNA construct and process for the fermentative production of fusion proteins
Abstract:	A DNA construct that allows the inexpensive production of a target protein in E. coli, consisting of a nucleic acid sequence encoding a signal peptide which is operably linked with a gene coding for a carrier protein which is linked with a gene coding for the target protein via a gene coding for a cleavable sequence S, wherein the gene coding for a carrier protein is the spy gene from E. coli.
Inventor(s):	Schloesser; Thomas (Wolfratshausen, DE), Dassler; Tobias (Munich, DE), Pfeiffer-Schwiesow; Kerstin (Munich, DE)
Assignee:	Wacker Chemie AG (Munich, DE)
Application Number:	11/924,019
Patent Claims:	1. A DNA construct for producing a target protein in E. coli, the DNA construct comprising a nucleic acid sequence encoding a signal peptide which is operably linked with a gene coding for a carrier protein which is linked with a gene coding for the target protein via a gene coding for a cleavable sequence S, wherein the gene coding for a carrier protein is a spy gene from E. coli wherein the spy gene comprises SEQ ID NO: 1 or a degenerate variant thereof. 2. The DNA construct of claim 1, wherein the nucleic acid sequence coding for the signal peptide is a nucleic acid encoding for the signal-peptide of the E. coli spy gene. 3. The DNA construct of claim 1, wherein the nucleic acid sequence codes for a target protein selected from the group consisting of interferons, interleukins, interleukin receptors, interleukin receptor antagonists, granulocyte-colony-stimulating factors, granulocyte-macrophage-colony-stimulating factors, macrophage-colony-stimulating factors, leukemia inhibitors, stem-cell growth factors, tumor necrosis factors, growth hormones, insulin-like growth factors, fibroblast growth factors, platelet-derived growth factors, transforming growth factors, hepatocyte growth factors, bone-morphogenetic factors, nerve growth factors, brain-derived neurotrophic factors (BDNF), glia-cell-line-derived neurotrophic factors, angiogenesis inhibitors, tissue plasminogen activators, blood clotting factors, trypsin inhibitors, elastase inhibitors, immunoglobulins, single-chain antibodies, complement components, hypoxia-inducing stress proteins, protein kinases, proto-oncogen products, transcription factors, virus-constitutive proteins, proinsulin, prourokinase, erythropoietin, thrombopoietin, neurotrophin, protein C, glucocerebrosidase, superoxide dismutase, renin, lysozyme, P450, prochymosin, lipocortin, reptin, serum albumin, streptokinase, tenecteplase, and CNTF (ciliary neurotrophic factor). 4. The DNA construct of claim 1, wherein the cleavable sequence S is a nucleic acid sequence that allows chemical or enzymatic cleavage of target and carrier protein in the translated fusion protein. 5. The DNA construct of claim 4, wherein the cleavable sequence S allows enzymatic cleavage of the fusion protein. 6. The DNA construct of claim 4, wherein the cleavable sequence S allows cleavage of the fusion protein by proteases. 7. The DNA construct of claim 6, wherein the cleavable sequence S allows cleavage of the target protein by eukaryotic protease factor Xa. 8. A plasmid comprising the DNA construct of claim 1. 9. A method of generating a fusion-protein-secreting microorganism strain, wherein the DNA construct of claim 1 is introduced into a microorganism strain from the family Enterobacteriaceae. 10. A method of generating a fusion-protein-secreting microorganism strain, wherein the plasmid of claim 8 is introduced into a microorganism strain from the family Enterobacteriaceae. 11. A microorganism strain comprising the DNA construct of claim 1. 12. A microorganism strain comprising the plasmid of claim 8. 13. A process for the fermentative production of a fusion protein by a microorganism strain, wherein a microorganism strain as claimed in claim 11 is cultured in a fermentation medium, during which process a fusion comprising a Spy protein, a target protein and a cleavable sequence (S) is formed, and, after the fermentation, the fermentation medium is separated from the cells of the microorganism strain. 14. The process of claim 13, wherein, after the fermentation medium has been separated off, the target protein is isolated from the periplasm of the cells, the carrier protein first being removed chemically or enzymatically from the target protein and the target protein subsequently being purified. 15. The process of claim 13, wherein, after the fermentation medium has been separated off, the target protein is isolated from the fermentation medium, the carrier protein first being removed chemically or enzymatically from the target protein and the target protein subsequently being purified.

Details for Patent 7,943,341

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	TNKASE	tenecteplase	For Injection	103909	06/02/2000		2026-10-25